Bowel cancer, also known as colorectal cancer, can affect any part of the colon or rectum; it may also be referred to as colon cancer or rectal cancer, depending on where the cancer is located.
Bowel cancer screening is for people who do not already have bowel cancer, symptoms of bowel cancer, or any reason to have a high risk of bowel cancer.
Patient-centred care is healthcare that is respectful of, and responsive to, the preferences, needs and values of patients and consumers.
Bowel Cancer Australia provides essential support services uniquely designed for bowel cancer patients via our confidential Helpline with specialist telehealth support, as well as a national Peer-to-Peer Support Network and Buddy Program.
Bowel Cancer Australia funds research that has the potential to improve survival and/or help build a path toward a cure and integrates published research into our awareness, advocacy, and support strategies.
Bowel Cancer Australia relies upon donations and the support of hard working and enthusiastic fundraisers across the country to continue our life saving work. We raise funds to continue our life-saving work and inspire others to do the same, so everyone affected by bowel cancer can live their best life.
Bowel Cancer Australia has announced a team led by Professor Michael Samuel as the successful applicant for a three-year $600k early-onset bowel cancer research project through the 2023 round of Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS).
Professor Samuel of the Centre for Cancer Biology (an alliance between the University of South Australia and SA Pathology) and the Basil Hetzel Institute for Translational Health Research will investigate ROCK-induced early-onset bowel cancer progression.
ROCK, Rho-associated kinase, is an enzyme (protein) found in all of us, that controls the shape and movement of cells within the body. ROCK goes into overdrive in people with bowel cancer, accelerating the growth and spread of the disease.
“As a Funding Partner of the PdCCRS, Bowel Cancer Australia sets its own research priorities and the categories to be funded in each round,” says Bowel Cancer Australia CEO, Julien Wiggins.
“Through the PdCCRS, we seek to support innovative and collaborative research across all aspects of early-onset bowel cancer (i.e. people diagnosed under age 50) that has the potential to improve survival and/or help build a path toward a cure,” he added.
“Bowel Cancer Australia remains grateful to our passionate fundraisers for their support and efforts in raising awareness and funds for early-onset bowel cancer, helping to make such research grants possible.”
Bowel cancer in the under fifties is trending upward, with 1-in-9 new bowel cancer cases now occurring in people under age 50, and presentation with metastatic disease more frequent in this demographic. Rates in the over fifties have stabilised or are declining.
The way in which cancer cells communicate with normal cells in their environment via ROCK has been discovered to drive disease progression (invasion, metastasis, and recurrence). This understanding has revealed that blocking cancers from hijacking normal cells in this way could be a new way to target the disease.
“People diagnosed with early-onset bowel cancer have a 50% chance that their cancer will recur or spread to other organs following initial intervention (e.g. surgery to remove the primary cancer), compared to around 30% in people diagnosed with late-onset bowel cancer,” says Professor Samuel.
“We have evidence that ROCK activity in bowel cancers drives this process by influencing how cancers communicate with their environment. Our project will investigate how this happens. We will also study whether certain effects of ROCK activation in early-onset bowel cancers can help us predict whose cancers will recur and whose will not,” he continues.
“In a practical sense, this could help us use targeted therapies that block cancer cells from communicating with their environment, in people who are most likely to experience recurrence of their cancer. It could also help us minimise the use of debilitating chemotherapies,” he adds.
Researchers will also be examining whether proteins that interact with ROCK cause early-onset bowel cancer progression, and if they do, targeting these proteins would be a way of stopping ROCK from accelerating tumour growth.
Through the PdCCRS, Bowel Cancer Australia ensures research supported by the charity is of a high standard and all Australian researchers have the opportunity to apply for funding.
Investigating ROCK-induced early-onset bowel cancer progression.
Bowel Cancer Australia was a Funding Partner for the 2023 Round of the Priority-driven Collaborative Cancer Research Scheme, with a $600,000 funding commitment over three years.
Through the Cancer Australia managed scheme, Bowel Cancer Australia supports innovative and collaborative research across all aspects of early-onset bowel cancer (i.e. people diagnosed under age 50) that has the potential to improve survival and/or help build a path toward a cure.
The Priority-driven Collaborative Cancer Research Scheme is an innovative annual national research project grants funding scheme which brings together government and other funders to collaboratively fund cancer research in Australia.
Cancer Australia collaborates with the National Health and Medical Research Council (NHMRC) in this grant scheme. The NHMRC facilitates registration and initial assessment of applications, and endorses grants funded through this scheme in recognition of their scientific merit.